Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Chronic Lymphocytic Leukemia
Clinical trial register · United States · industry-sponsored

Chronic Lymphocytic Leukemia Trials in the USA, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9132 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 10 Oct 2026, 03:16 UTC
9132
Studies in scope
industry-sponsored, all four open statuses
4964
Recruiting now
open to new participants
2194
Lead sponsors
across recruiting studies
Top states
Florida 30 California 27 Illinois 19 Arizona 16 Massachusetts 15
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Acerta Pharma BV7 BeOne Medicines6 Loxo Oncology, Inc.5 AbbVie5 Merck Sharp & Dohme LLC3
State
Florida30 California27 Illinois19 Arizona16 Massachusetts15
All 41 states
Target enrolment
to

Chronic Lymphocytic Leukemia trials in the USA

45 of 9132 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Not yet open
BAFF CAR-T Cells (LMY-922) for Treatment of Refractory Hematologic Malignancies
NCT07679919Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Hairy Cell Leukemia, Multiple Myeloma
DrugLMY-922
Luminary Therapeutics
Phase 1
27
Ohio
2026-09
Recruiting
Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL
NCT07516093B-cell Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
DrugsBexobrutideg·Pirtobrutinib
Nurix Therapeutics, Inc.
Phase 3
620
Georgia, Indiana, Tennessee, Texas, Virginia
2026-08-03
Recruiting
Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies
NCT07520006B-cell Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
DrugsBexobrutideg·Obinutuzumab·Venetoclax·Rituximab
Nurix Therapeutics, Inc.
Phase 1/2
150
Colorado, Florida, Oregon, Pennsylvania, Tennessee, Texas
2026-08
Recruiting
Curis, Inc.
Phase 2
108
Florida, Minnesota, New Jersey, Ohio, Pennsylvania, Texas
2026-04-23
Recruiting
Eli Lilly and Company
Phase 4
150
Alabama, Arizona, Florida, Minnesota, New York, Ohio, Texas
2026-03-09
Recruiting
BeOne Medicines
Phase 3
500
California, Colorado, Florida, Illinois, Louisiana, Massachusetts, Minnesota, Nebraska
2026-01-22
Recruiting
BeOne Medicines
Phase 3
500
Alabama, Arizona, California, Delaware, District of Columbia, Florida, Illinois, Iowa
2025-09-04
Recruiting
BeOne Medicines
Phase 3
630
California, Colorado, Connecticut, Florida, Illinois, Iowa, Kentucky, Louisiana
2025-06-11
Recruiting
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
NCT06533579B-cell Acute Lymphoblastic Leukemia, Large B-cell Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Vironexis Biotherapeutics Inc.
Phase 1/2
32
California, Colorado, Florida, Minnesota, New York, North Carolina, Ohio, Oregon
2025-05-30
Recruiting
Eli Lilly and Company
Phase 4
279
Florida, Georgia, Illinois, Massachusetts, Minnesota, Nebraska, New York, North Carolina
2025-05-20
Recruiting
A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
NCT06876649Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma
DrugPirtobrutinib
Eli Lilly and Company
Phase 4
787
Florida, Georgia, Illinois, Massachusetts, Minnesota, Nebraska, New York, North Carolina
2025-05-20
Recruiting
BeOne Medicines
Phase 3
250
Arkansas, California, Colorado, Florida, Georgia, Louisiana, Maryland, Michigan
2025-04-10
Active, closed
AbbVie
Phase 1
4
California, Montana, North Carolina, Texas
2025-01-27
Recruiting
BeOne Medicines
Phase 1/2
258
Florida, Indiana, Kansas, Massachusetts, Missouri, Washington
2025-01-23
Recruiting
Loxo Oncology, Inc.
Phase 2
249
Arizona, California, Colorado, Florida, Georgia, Iowa, Kentucky, Maryland
2025-01-03
Active, closed
BeOne Medicines
Phase 2
94
Florida, Georgia, Illinois, Maryland, Nebraska, Oregon, Texas, Utah
2024-11-14
Active, closed
Genentech, Inc.
Phase 2
118
Arkansas, Colorado, Florida, Indiana, Iowa, Maryland, Massachusetts, Nebraska
2024-08-09
Recruiting
AbbVie
Phase 3
170
Arizona, California, Colorado, Connecticut, Florida, Illinois, Indiana, Iowa
2024-08-05
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,200
Alabama, Arizona, California, Colorado, Connecticut, Florida, Idaho, Indiana
2023-12-13
Recruiting
AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
NCT05602363B-cell Malignancy, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Waldenstrom Macroglobulinemia
Carna Biosciences, Inc.
Phase 1
120
California, Florida, Illinois, Indiana, Maryland, Massachusetts, New York, North Carolina
2023-08-01
Active, closed
Study Evaluating SC291 in Subjects With r/r B-cell Malignancies (ARDENT)
NCT05878184Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia
DrugsSC291·Fludarabine·Cyclophosphamide
Sana Biotechnology
Phase 1
16
California, Georgia, Kansas, Michigan, Nebraska, Texas
2023-05-02
Active, closed
AbbVie
Phase 1
39
Arizona, Florida, Minnesota, Nebraska, New York, North Carolina, Texas
2023-04-26
Active, closed
Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets
NCT05618028Diffuse Large B-Cell Lymphoma, Chronic Lymphocytic Leukemia, B Cell Malignancies, Non-Hodgkin's Lymphoma
AbbVie
Phase 1
78
California, Connecticut, Florida, Indiana, Louisiana, Michigan, New York, North Carolina
2023-04-04
Active, closed
Merck Sharp & Dohme LLC
Phase 3
300
Arkansas, Florida, Mississippi, Washington
2023-03-16
Recruiting
A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
NCT05254743Chronic Lymphocytic Leukemia, Leukemia, Lymphocytic, Leukemia, B-cell, Small Lymphocytic Lymphoma
DrugsPirtobrutinib·Ibrutinib
Loxo Oncology, Inc.
Phase 3
737
California, Florida, Louisiana, Maryland, Montana, Pennsylvania, South Carolina, Tennessee
2022-07-22
Active, closed
A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006)
NCT05458297Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Follicular Lymphoma, Richter Transformation Lymphoma
DrugsZilovertamab vedotin·Nemtabrutinib
Merck Sharp & Dohme LLC
Phase 2
189
Alaska, Arizona, Colorado, Illinois, Kansas, Kentucky, Maryland, Massachusetts
2022-07-21
Active, closed
Loxo Oncology, Inc.
Phase 3
282
California, Florida, New Jersey, New York
2021-09-23
Active, closed
Loxo Oncology, Inc.
Phase 3
600
Arizona, California, Connecticut, Florida, Iowa, Kentucky, Maryland, Massachusetts
2021-09-20
Active, closed
FT819 in Subjects With B-cell Malignancies
NCT04629729Lymphoma, B-Cell, Chronic Lymphocytic Leukemia, Precursor B-Cell Acute Lymphoblastic Leukemia
DrugsFT819·Fludara·Aldesleukin·Bendamustine
Fate Therapeutics
Phase 1
54
Alabama, Arizona, California, Florida, Iowa, Kansas, Kentucky, Minnesota
2021-07-12
Active, closed
Loxo Oncology, Inc.
Phase 3
238
Alabama, Arizona, California, Colorado, Delaware, Florida, Georgia, Illinois
2021-03-09
Recruiting
Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL
NCT04502394Diffuse Large B Cell Lymphoma, Chronic Lymphocytic Leukemia, Non Hodgkin Lymphoma
DrugsNavtemadlin·Acalabrutinib
Kartos Therapeutics, Inc.
Phase 1/2
84
Indiana, Ohio, Texas
2021-02-23
Active, closed
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
NCT03844048Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia, Multiple Myeloma, Non-Hodgkin's Lymphoma
DrugsVenclexta·Venetoclax
AbbVie
Phase 3
165
Arizona, California, Illinois, Massachusetts, Michigan, New Hampshire, Washington
2019-09-06
Active, closed
Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL
NCT03960840Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Diffuse Large B-cell Lymphoma, Acute Lymphoblastic Leukemia
DrugIbrutinib
Novartis Pharmaceuticals
Phase 1/2
217
California, Florida, Illinois, Kansas, Massachusetts, Pennsylvania, Tennessee, Texas
2019-06-26
Recruiting
Imugene Limited
Phase 1
135
Florida, Georgia, Maryland, Massachusetts, Minnesota, New York, Rhode Island, Texas
2019-03-11
Active, closed
Acerta Pharma BV
Phase 3
984
California, Indiana, Kansas, Kentucky, Louisiana, Maryland, Massachusetts, New York
2019-02-25
Active, closed
BeiGene
Phase 3
590
Georgia, Illinois, Massachusetts, Missouri, Nevada, New Jersey, New York, North Carolina
2017-10-31
Active, closed
Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in Waldenstrom
NCT02952508Waldenstrom Macroglobulinemia, Multiple Myeloma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
DrugCLR 131
Cellectar Biosciences, Inc.
Phase 2
120
California, District of Columbia, Florida, Georgia, Illinois, Kansas, Louisiana, Maryland
2017-07-26
Active, closed
A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001)
NCT03162536Lymphoma, B-Cell, Small Lymphocytic Lymphoma, Chronic Lymphocytic Leukemia, Waldenstrom Macroglobulinemia
DrugNemtabrutinib
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Phase 1/2
190
Arizona, California, Colorado, Michigan, Minnesota, North Carolina, Ohio, Tennessee
2017-06-26
Active, closed
Acerta Pharma BV
Phase 3
310
Arizona, California, Georgia, Illinois, Iowa, Kentucky, Minnesota, Nebraska
2017-02-02
Active, closed
Acerta Pharma BV
Phase 2
60
Arizona, California, District of Columbia, Illinois, New York, Ohio, Tennessee, Texas
2016-03-08
Active, closed
Acerta Pharma BV
Phase 3
533
Arizona, California, Florida, Georgia, Illinois, Kansas, Minnesota, Montana
2015-07-28
Active, closed
Acerta Pharma BV
Phase 3
535
Arizona, California, Colorado, District of Columbia, Florida, Illinois, Indiana, Kansas
2015-06-26
Active, closed
Acerta Pharma BV
Phase 1
12
Ohio, Tennessee, Texas
2014-08-18
Active, closed
ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (BTK) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic Leukemia
NCT02029443Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Richter's Syndrome, Prolymphocytic Leukemia
DrugAcalabrutinib
Acerta Pharma BV
Phase 1/2
306
Massachusetts, New York, Ohio, Texas, Utah, Washington
2014-01-30
Active, closed
A Long-term Extension Study of PCI-32765 (Ibrutinib)
NCT01804686Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma
DrugIbrutinib
Janssen Research & Development, LLC
Phase 3
539
California, Connecticut, Georgia, Illinois, Indiana, Kansas, Kentucky, Massachusetts
2013-09-09
Rows per page Showing 1–45 of 45
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 10 October 2026. https://priyalifescience.com/clinical-trials-usa/condition/chronic-lymphocytic-leukemia

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the US and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,132 studies in total at the last sync on 10 Oct 2026, 03:16 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 45 of those studies listing the condition Chronic Lymphocytic Leukemia.

How many Chronic Lymphocytic Leukemia trials are recruiting in the US?

19 of the 45 studies on this page are recruiting new participants as of the 10 Oct 2026, 03:16 UTC sync. A further 1 have not yet opened recruitment, 25 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Chronic Lymphocytic Leukemia), 45 studies
PhaseStudiesRecruitingShare
Phase 319842.2%
Phase 19220%
Phase 1/27415.6%
Phase 27215.6%
Phase 4336.7%

Most active sponsors

Lead sponsors with the most studies (Chronic Lymphocytic Leukemia)
Lead sponsorStudiesRecruiting
Acerta Pharma BV70
BeOne Medicines65
AbbVie51
Loxo Oncology, Inc.52
Eli Lilly and Company33
Merck Sharp & Dohme LLC31
Nurix Therapeutics, Inc.22
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)10
BeiGene10
Carna Biosciences, Inc.11

Top states

Top states (Chronic Lymphocytic Leukemia), by number of studies with a site there
StateStudies
Florida30
California27
Illinois19
Arizona16
Massachusetts15
Georgia14
Texas14
Colorado13
New York13
Minnesota12
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.